Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.
StockStory.org on MSN
Pfizer earnings: What to look for from PFE
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors ...
Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...
The pharmaceutical giant just extended the lifespan of one of its top drugs.
Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
Hosted on MSN
Pfizer lags as Cadrenal advances to Phase 3 trial
Pfizer shares remain under pressure amid declining COVID vaccine demand, looming patent expirations, and delays in entering the GLP-1 weight-loss market. Meanwhile, Cadrenal Therapeutics gained ...
By Padmanabhan Ananthan May 1 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer and Arvinas' breast ...
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...
Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...
Pfizer Inc. (NYSE:PFE) ranks among the best low-risk investments in May 2026. On April 13, Guggenheim reaffirmed a Buy rating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results